Skip to main content
OpenTrials
Completed

NCT Number: NCT00588042

Remote Myocardial Ischemic Preconditioning in Humans

Ischemic preconditioning (IP) has been shown in animal studies to increase the myocardial tolerance to subsequent ischemia. Our primary hypothesis is that remote IP reduces myocardial ischemic injury during PCI.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Mayo Clinic

Rochester, Minnesota, 55905, United States

About this study

Our primary hypothesis is that remote IP reduces myocardial ischemic injury during PCI. We will also test the hypotheses that IP diminishes the inflammatory response to PCI, and that higher baseline blood endothelial progenitor cell counts are predictive of a favorable response to IP.

Aim 1: To evaluate whether remote ischemic preconditioning reduces the frequency of myonecrosis (troponin T≥0.03 ng/ml following PCI).

Aim 2: To evaluate whether remote ischemic preconditioning reduces the inflammatory response to PCI (post PCI hsCRP level).

Aim 3: To evaluate whether pre-procedure circulating endothelial progenitor cell counts correlate with the effect of remote ischemic preconditioning on myonecrosis.

Background: Percutaneous coronary intervention (PCI) frequently results in ischemic myonecrosis. Ischemic preconditioning (IP) has been shown in animal studies to increase the myocardial tolerance to subsequent ischemia. Our primary hypothesis is that remote IP reduces myocardial ischemic injury during PCI.

Aims: The aims of the study are to assess in patients with coronary artery disease requiring PCI, whether remote IP reduces: 1) the frequency of myonecrosis; and 2) the inflammatory response to PCI; and 3) whether the effect of IP correlates with pre-procedure circulating endothelial progenitor cell counts.

Methods: The study is a prospective, randomized trial to assess the efficacy of remote IP as adjunctive non-pharmacological therapy for PCI in patients with stable or unstable angina. Remote IP will be performed by 3 cycles of 3-minutes of arm ischemia alternating with 3- minutes of reperfusion of the arm immediately before PCI. Myonecrosis and inflammation will be detected by measuring serum troponin T and high sensitivity C-reactive protein, respectively. Blood EPC counts will also be measured before the procedure.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients will be eligible for randomization if they meet the following criteria:
  • Age ≥ 18 years
  • Clinically indicated elective or urgent PCI

Exclusion criteria

  • Patients will be ineligible for the study if one or more of the following conditions exist:
  • Pre-PCI Troponin T ≥ 0.03
  • Systemic hypotension (systolic <90 mmHg) or cardiogenic shock
  • Presence of an arteriovenous fistula or lymphedema of either arm
  • Currently enrolled in other active cardiovascular investigational studies
  • Severe endocrine, hepatic, renal, disorders
  • Pregnancy or lactation
  • Inability to provide consent
  • Federal Medical Center inmates
  • Inability or unwillingness to provide informed consent

Treatment and study plan

blood pressure cuff

Device

Arm ischemia will be induced using a blood pressure cuff that will be placed around the upper part of the arm, and inflated to 200 mm Hg for 3-minutes and then deflated for 3-minutes

Other names: sphygmomanometer

Primary outcomes

  1. Post PCI myonecrosis measured as a maximum troponin T ≥0.03

    Time frame: 16 hours post PCI

Secondary outcomes

  1. Post PCI myonecrosis measured as an elevation in creatine kinase MB fraction (CK-MB> 1 X upper limit of normal)

    Time frame: 16 hours post procedure

  2. Magnitude of ST segment elevation on an intracoronary electrocardiogram during balloon inflation

    Time frame: During PCI procedure

  3. Coronary perfusion measured as coronary flow reserve derived from TIMI frame counts

    Time frame: During PCI

  4. Blood high sensitivity C-reactive protein level

    Time frame: Immediately prePCI

  5. Blood endothelial progenitor cell counts (EPC)

    Time frame: Immediately prePCI

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Acronym: RemoteMIPH

Important dates

Study start
2007
Primary completion
2009
Study completion
2009
First posted
Jan 8, 2008
Registry last updated
Apr 17, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.